Turnstone Biologics Corp. Common Stock (TSBX) — Cash Flow-to-Debt Ratio
Turnstone Biologics Corp. Common Stock (TSBX) has a Cash Flow-to-Debt Ratio of -0.68x as of June 2025, meaning its operating cash flow of $-4.30 Million could theoretically repay -1% of its total liabilities ($6.34 Million) in one year. See TSBX financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Turnstone Biologics Corp. Common Stock Cash Flow-to-Debt Ratio (2021–2024)
Historical debt coverage capacity for Turnstone Biologics Corp. Common Stock across 4 annual periods. For the full cash flow conversion analysis, see TSBX cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Turnstone Biologics Corp. Common Stock (2021–2024)
Year-by-year debt coverage analysis for Turnstone Biologics Corp. Common Stock. Check cash flow quality index of Turnstone Biologics Corp. Common Stock to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -7.78x | $-67.44 Million | $8.67 Million | ▼ -66.3% |
| 2023 | -4.68x | $-66.15 Million | $14.15 Million | ▼ -1323.9% |
| 2022 | -0.33x | $-71.06 Million | $216.41 Million | ▼ -93.7% |
| 2021 | -0.17x | $-45.63 Million | $269.10 Million | — |